Premium
Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions
Author(s) -
Thota Swapna,
Patel Bhumika J.,
Sadaps Meena,
Balasubramanian Suresh,
Sanikommu Srinivasa,
Hirsch Cassandra,
Marotta Serena,
Sekeres Mikkael A.,
Risitano Antonio M.,
Maciejewski Jaroslaw P.
Publication year - 2018
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14907
Subject(s) - alemtuzumab , medicine , cd52 , bone marrow , aplastic anemia , immunology , bone marrow failure , stem cell , haematopoiesis , antibody , biology , genetics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom